Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy

Eri Katsuyama, Hiroshi Wakabayashi, Ken Ei Sada, Sumie Hiramatsu, Yoshia Miyawaki, Michiko Morishita, Keiji Ohashi, Haruki Watanabe, Takayuki Katsuyama, Sonia Zeggar, Mariko Narazaki, Noriko Tatebe, Katsue S. Watanabe, Tomoko Kawabata, Jun Wada

Research output: Contribution to journalArticlepeer-review

Abstract

We herein present a case of a 38-year-old man who had bamboo spine and severe sacroiliitis and who was diagnosed with ankylosing spondylitis (AS). Infliximab (IFX) markedly improved the axial symptom but was discontinued due to the side effect of peripheral neuropathy. Switching from IFX to etanercept worsened the side effect. Rituximab (RTX) administration elicited a good response without side effects. RTX might be a suitable option for AS therapy when TNF inhibitors are difficult to use.

Original languageEnglish
Pages (from-to)445-448
Number of pages4
JournalActa medica Okayama
Volume71
Issue number5
Publication statusPublished - 2017

Keywords

  • Ankylosing spondylitis
  • Rituximab
  • Treatment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Alternative to Rituximab therapy for a patient with ankylosing spondylitis who was unable to continue anti-TNF therapy'. Together they form a unique fingerprint.

Cite this